Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN035 in Patients With Advanced Multiple Primary Tumors
NCT04182789Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in Multiple Primary Tumors and colorectal cancer (CRC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
envafolimab
03
Conditions
Multiple Primary Tumorscolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04182789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182789.